Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aurobindo Files First Biosimilar In Europe With Pegfilgrastim

Indian Giant’s CuraTeQ Subsidiary Files BP14 Neulasta Rival With EMA

Executive Summary

Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.

You may also be interested in...

Aurobindo’s CuraTeQ Withdraws European Biosimilars – But They Will Be Back

Aurobindo’s CuraTeQ has withdrawn EMA filings for its filgrastim and pegfilgrastim biosimilars over inspection timing issues – but expects to refile the products as it works towards obtaining the necessary EU GMP certification.

Aurobindo Seeks To Boost India Business With Veritaz Acquisition

Aurobindo is looking to grow its business in India by acquiring Veritaz’s domestic formulations operations in a $22.4m slump sale.

Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit

Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts